

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/087,951		
		Filing Date	03/05/2002		
		First Named Inventor	Donald L. Barbeau		
		Group Art Unit	1751		
		Examiner Name			
Sheet	2	of	4	Attorney Docket Number	Barbeau 0302

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RR		DRUERY, J. AND MARXER, A. Hypotensive Hydrazinophthalines and Related Compounds, Journal of Medicinal and Pharmaceutical Chemistry 1(1): 1-21 (1959) Johnson Reprint Corporation New York	
RR		SHEPHERD, A. et al. Hydralazine kinetics after single and repeated oral doses, Clinical Pharmacology and Therapeutics 28(6): 804-811(1980)	
RR		LUDDEN, T.M. et al. Hydralazine kinetics in hypertensive patients after single intravenous administration, Clinical Pharmacology and Therapeutics 28(6): 736-742(1980)	
RR		HAEGELE K.D. et al. Quantitative Analysis of Hydralazine Pyruvic Acid Hydrazone, The Major Metabolite of Hydralazine Journal of Chromatography 187:171-179 (1980)	
RR		CLEMENTI, W.A. et al. Endogenous Generation of Hydralazine from Labile Hydralazine Hydrazones, Journal of Pharmacology and Experimental Therapeutics 222(1):159-165 (1982)	
RR		OGISO, T. et al. Pharmacokinetics of Formation and Excretion of Some Metabolites of Hydralazine and Their Hypotensive Effect in Rats, Journal of Pharmacology and Experimental Therapeutics 233(2):485-490 (1985)	
RR		IWAKI, M. et al. In Vitro Kinetic Studies of the Reaction of Hydralazine and its Acetone Hydrazone with Pyruvic Acid, Journal of Pharmaceutical Sciences 77(3):280-283 (1988)	
RR		McLEAN, A.J. et al. Interaction of Hydralazine and Hydrazone Derivatives with Contractile Mechanisms in Rabbit Aortic Smooth Muscle, Journal of Pharmacology and Experimental Therapeutics 205(2): 418-425 (1978)	
RR		HAEGELE, K.D. et al. Identification of Hydralazine and Hydralazine Hydrazone Metabolites in Human Body Fluids and In Vitro Comparisons of their Smooth Muscle Activity British, Journal of Clinical Pharmacology 5:489-494 (1978)	
RR		BARRON, K. et al. Comparative Evaluation of the in vitro Effects of Hydralazine and Hydralazine Acetonide on Arterial Smooth Muscle, British Journal of Pharmacology 621:345-349 (1977)	
RR		ISRAILI, Z.H. and DAYTON, P.G. Metabolism of Hydralazine Drug, Metabolism Reviews 6(2):283-305 (1977)	

Examiner Signature	<i>R. Raymond</i>	Date Considered	1-7-04
--------------------	-------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
NOV 27 2002
TECH CENTER 1600/2900

RECEIVED
NOV 26 2002
TC 1700



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/087,951
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	03/05/2002
		First Named Inventor	Donald L. Barbeau
		Group Art Unit	1751
		Examiner Name	
		Attorney Docket Number	Barbeau 0302
Sheet	3	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RR		O'DONNELL, J.P. et al. Kinetic Studies of Hydralazine Reaction with Acetaldehyde, Journal of Pharmaceutical Sciences 68(10): 1256-1258 (1979)	
RR		ZIMMER, H., A Major Metabolite of 1-Hydrazinophthalazine, Arznei-Forsch 20(10):1586-1587 (1970)	
RR		TALSETH, T. Pharmacokinetics and Cardiovascular Effects in Rabbits of a Major Hydralazine Metabolite, the Hydralazine Pyruvic-Acid Hydrazone 211(3):509- 513 (1979)	
RR		McLEAN, A.J. et al. Study of In Vitro Effects of Hydralazine Metabolites -Comparative Evaluation of Products of Hydroxylation, Hydrolysis and Conjugation, Archives International Pharmacodynamics 235:19-25 (1978)	
RR		LaCAGNIN, L.B. et al. Metabolic Activation of Hydralazine by Rat Liver Microsomes, Biochemical Pharmacology 36(16): 2667-2672 (1987)	
RR		LESSEN, T. A et al. Interactions between Drug Substances and Excipients. 1. Fluorescence and HPLC Studies of Triazophthalazine Derivatives from Hydralazine Hydrochloride and Starch Journal of Pharmaceutical Sciences 85(3): 326-329 (1996)	
RR		SCHNECK, D.W. et al. Plasma levels of free and acid-labile hydralazine: Effects of multiple dosing and of procainamide Clinical Pharmacology and Therapeutics 24(6): 714-719 (1978)	
RR		TALSETH T. et al. Hypotensive Effect of the Hydralazine-Acetone Hydrazone in Conscious Rabbits: Evidence for its Back-Conversion to Hydralazine In Vivo, Journal of Cardiovascular Pharmacology 4: 370-374 (1982)	
RR		McLEAN, A.J. et al. Comparative Evaluation of the Hypotensive Activity of Two Major Metabolites of Hydralazine (1-Hydrazinophthalazine) European Journal of Drug Metabolism and Pharmacokinetics 1: 17-20 (1977)	
RR		JUCHAU, M.R. AND HORITA, A. Metabolism of Hydralazine Derivatives of Pharmacological Interest, Drug Metabolism Reviews 1(1): 71-100 (1972)	
RR		HAEGELE, K.D. et al. Determination of Hydralazine and Its Metabolites by Gas Chromatography-Mass Spectrometry Journal of Chromatography 126:517-534 (1976)	

Examiner Signature	<i>RR [Signature]</i>	Date Considered	1-7-04
--------------------	-----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

RECEIVED
NOV 2 7 2002

NOV 2 6 2002
FC 1700

RECEIVED



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/087,951
		Filing Date	03/05/2002
		First Named Inventor	Donald L. Barbeau
		Group Art Unit	1751
		Examiner Name	
Sheet	4	of	4
		Attorney Docket Number	Barbeau 0302

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RR		LUDDEN et al., High-Pressure Liquid Chromatography Assay for Hydralazine in Human Plasma, Journal of Pharmaceutical Sciences 63(11) 1423-1425(1979)	
RP		O'DONNELL, J.P., et al., High-Pressure Liquid Chromatography Studies of Reaction of Hydralazine in with Biogenic Aldehydes and Ketones, Journal of Pharmaceutical Sciences 68(12) 1524-1526(1979)	
RR		REECE, P.A., et al. Selective High-Performance Liquid Chromatographic Assays for Hydralazine and its Metabolites in Plasma of Man, Journal of Chromatography 181:427-440 (1980)	
RP		LACAGNIN, L.B. Separation and Quantitation of Hydralazine Metabolites by High-Performance Liquid Chromatography, Journal of Chromatography 377:319-327 (1986)	
RR		IWAKA, M. ET AL. Pharmacokinetics and Biotransformation of Hydralazine Acetone Hydrazone, a Metabolite of Hydralazine, in the Rat, Journal of Pharmaceutical Sciences 78(10):867-873(1989)	
RR		KANAZAWA, H. et al. New Degradation Products in an Aqueous Solution of Hydralazine Hydrochloride with Cimetidine, Chem. Pharm. Bull. 34(4):1840-1842 (1986)	
RR		SCHULER, W. AND WYSS, E., Zur Frage Der Spezifitat Der Wirkung Blutdrucksenkender Und Rerpinin-Antagonistisch... Arch. Int. Pharmacodyn. CXXVIII(3-4):431- 468 (1960)	

Examiner Signature	<i>RR Raym</i>	Date Considered	1-7-01
--------------------	----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

RECEIVED
NOV 27 2002

RECEIVED
NOV 26 2002

TC 1700